The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

Note that some links may require registration or subscription. The Trump administration is set to announce a proposed rule ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Shares of Eli Lilly (NYSE: LLY) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for ...

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...